| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | estradiol (Lenzetto®) |
| Formulation | 1.53 mg transdermal spray |
| Reference number | 4622 |
| Indication | Sequential hormone replacement therapy (HRT) for oestrogen deficiency symptoms in postmenopausal women (in women at least 6 months since last menses or surgical menopause, with or without a uterus). The experience in treating women older than 65 years is limited |
| Company | Gedeon Richter UK Ltd |
| BNF chapter | Endocrine system |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 10/09/2020 |